LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) granted stock options and restricted stock units covering a total of 15,000 shares to a newly hired employee on February 10, 2026, the company announced.
The awards were approved by the Compensation Committee of Savara’s Board of Directors under the company’s 2021 Inducement Equity Incentive Plan and were granted in accordance with Nasdaq Listing Rule 5635(c)(4), which permits equity awards as an inducement to employment.
The inducement package includes options to purchase 7,500 shares of common stock and restricted stock units, or RSUs, covering 7,500 shares.
The options have an exercise price of $5.27 per share, equal to the closing price of Savara’s common stock on the Nasdaq Global Market on the grant date. The options have a 10-year term and vest in equal installments of one-sixteenth on each quarterly anniversary of the employee’s first day of employment, subject to continued employment.
The RSUs will vest in full on the two-year anniversary of the employee’s start date, subject to continued employment, according to the announcement.
Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Its lead product candidate, MOLBREEVI, is in Phase 3 development for autoimmune pulmonary alveolar proteinosis and is delivered through an investigational nebulizer system developed for inhalation therapy.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.